Podcasts about zymergen

Episode Description: Karl and Erum bring you the latest innovations highlighted at SynbioBeta 2024, focusing on the exciting intersection of AI and biotechnology. Hear about the groundbreaking work from the ARC Institute in whole genome sequencing and the newest advancements in AI-driven protein synthesis that are set to change the landscape of synthetic biology. They also touch on the potential of bioluminescent plants and the latest progress in space biomanufacturing. With expert insights and firsthand accounts from the conference, this episode offers a glimpse into the future of biotech and AI, sparking curiosity and excitement for what's to come. Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing? Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters: 00:00:00 - Recapping SynbioBeta 2024: Networking and Recognition 00:02:47 - AI and Biotech: Insights and Innovations 00:09:37 - Space and Bio-Manufacturing: The Final Frontier 00:12:15 - AI Biotech Track: Key Sessions and Speakers 00:14:54 - DNA Synthesis and the Future of Medicine 00:17:21 - Exploring the World of Psychedelics 00:22:55 - The Power of Traditional and Natural Medicines 00:26:42 - Psychedelics and Mental Health: Emerging Research 00:30:59 - Investor Insights: Focusing on Problem-Solving 00:35:34 - Navigating the Conference: Strategies and Success Stories 00:37:56 - Networking and Connections: The Heart of Conferences 00:40:52 - The Light Bio Plant Saga: A Case Study in Consumer Experience 00:45:41 - Exploring Biotech Through Art and Culture 00:50:27 - Celebrating Achievements and Community at SynbioBeta 00:53:44 - The Expo Hall Experience: Swag and Innovations 01:00:29 - Looking Forward: The Future of Conferences and Biotech Episode Links: AlphaFold 3.0 ESMfold  Synbiobeta Arc Institute  BioAstra Interstellar Lab Francis Crick Institute Starburst Aerospace Paul Stamets MycoMedica Life Sciences Abolis Biotechnologies Debut Biotech L'Oreal Startup Accelerator  K18 Hair  Zymergen acquired by Gingko story  Amyris  Tom Baruch Medium articles  External Womb Video  Andy Bass's bioluminescent work  United Therapeutics Japanese Anime The Next 500 Years by Chris Mason  Mycelium Running by Paul Stamets Topics Covered:  space, biotech, psychedelics, Ai, natural intelligence, synbiobeta conference, synthetic biology, DNA writing, DNA synthesis, precision fermentation, beauty Have a question or comment? Message us here: Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GrowEverything website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email: groweverything@messaginglab.com Support here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

Episode Description: Alex Rosay of Cascade Biocatalysts joins us as we delve into the groundbreaking realm of enzyme technology and its transformative impact on various industries. We navigate through the innovative world of cell-free biotechnological solutions, highlighting how these advancements are revolutionizing traditional fermentation processes and offering more sustainable, efficient alternatives. We explore the diverse applications of enzymes, from food ingredients to bio-mining, and the challenges and triumphs in stabilizing these biological catalysts. This episode is a fascinating journey into the heart of biotech innovation, showcasing how nature-inspired solutions are shaping a more sustainable industrial future. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space.  Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00 - Meet Alex Rosay and Dive into Enzyme Technology 00:07:48 - The Game-Changing Innovation: Cell-Free Biomanufacturing 00:10:43 - How Biology is Revolutionizing Industries Worldwide 00:11:26 - Insights from Zymergen's Success and Navigating Office Dynamics 00:16:04 - Learning from Zymergen Challenges: Building Stronger Biotech Businesses 00:20:56 - The Scale of Cell-Free Biology: Transforming Manufacturing 00:23:00 - Industry Perspectives on Enhancing Biotech Startups 00:28:30 - Inside Biotech Innovation: Enzyme Production and Stability 00:31:00 - Pioneering Green Technologies: The Next Decade in Biotech 00:36:43 - The Enzymatic Future: Biotech's Role in Brewing and Beyond 00:40:00 - Navigating Startup Challenges: Intellectual Property and Market Competition 00:44:15 - Biological Innovation: Green Materials and Sustainable Industries 00:46:30 - Peering into the Biotech Landscape: Predicting the Next Three Years 00:49:00 - Behind the Scenes: Research and Development in Biotech 00:51:15 - Shaping Traditional Manufacturing with the Power of Biology 00:53:45 - Biotech's Impact on Environmental Sustainability in the Real World Episode Links: LinkedIn Cascade Biocatalysts Have a question or comment? Message us here: Text or Call (804) 505-5553 Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

https://www.patreon.com/datameshradio (Data Mesh Radio Patreon) - get access to interviews well before they are released Episode list and links to all available episode transcripts (most interviews from #32 on) https://docs.google.com/spreadsheets/d/1ZmCIinVgIm0xjIVFpL9jMtCiOlBQ7LbvLmtmb0FKcQc/edit?usp=sharing (here) Provided as a free resource by DataStax https://www.datastax.com/products/datastax-astra?utm_source=DataMeshRadio (AstraDB); George Trujillo's contact info: email (george.trujillo@datastax.com) and https://www.linkedin.com/in/georgetrujillo/ (LinkedIn) Transcript for this episode (https://docs.google.com/document/d/14uVlti-v7tHuZVE3KKOGaeqDPKE018LOVFfdVjUWhmQ/edit?usp=sharing (link)) provided by Starburst. See their Data Mesh Summit recordings https://www.starburst.io/learn/events-webinars/datanova-on-demand/?utm_campaign=starburst-brand&utm_medium=outbound&utm_source=&utm_type=&utm_content=dmradiodnvid&utm_term= (here) and their great data mesh resource center https://www.starburst.io/info/distributed-data-mesh-resource-center/?utm_campaign=starburst-brand&utm_medium=outbound&utm_source=&utm_type=&utm_content=dmradiodmcenter&utm_term= (here). You can download their Data Mesh for Dummies e-book (info gated) https://starburst.io/info/data-mesh-for-dummies/?utm_campaign=starburst-brand&utm_medium=outbound&utm_source=&utm_type=&utm_content=dmradiodnvid&utm_term= (here). Dmitriy's Twitter: @squarecog / https://twitter.com/squarecog (https://twitter.com/squarecog) The Missing README book: https://themissingreadme.com/ (https://themissingreadme.com/) Building Evolutionary Architectures book: https://www.oreilly.com/library/view/building-evolutionary-architectures/9781491986356/ (https://www.oreilly.com/library/view/building-evolutionary-architectures/9781491986356/) In this episode, Scott interviewed Dmitriy Ryaboy, CTO at Zymergen and co-author of the book The Missing README. Some key takeaways/thoughts from Dmitriy's point of view: Organizational design and change management is "like a knife fight" - you are going to get cut but if you do it well, you can choose where you get cut. There is no perfect org, and there will be pain somewhere but you can influence what will hurt, and make it not life-threatening. There is too much separation between data engineering and software engineering. Data engineering is just a type of software engineering with a focus on dealing with data. We have to stop treating them like completely different practices. When communicating internally, always focus on telling people the why before you get to the how. If they don't get why you are doing it, they are far less likely to be motivated to address the issue or opportunity. This applies to getting teams to take ownership of the data they produce, but also to everything else. There is often a rush to use tech over talk. Conversation is a powerful tool and will set you up so your tools can help you address the challenges once people are aligned. Paving over challenges with tech will not go well. Build your data platform such that the central data platform team is unnecessary in conversations between data producers and data consumers. That way, your team won't become a bottleneck. Try to reduce cognitive load on the users - they shouldn't have to deeply understand the platform and its inner workings just to leverage it. "Data debt is debt forever." You can certainly 'pay it down' but data debt typically has a much longer life than even the initial source system that supplied the data. Take it on consciously. Looking to hire or grow full-stack engineers for an ever-growing definition of stack (backend, frontend, security, ops, QA, UX, data...) is probably not a great idea, we can't keep piling new domains on people and expect them to be good at all of them. Instead, look to build full-stack teams, and tools that look and feel sufficiently similar that e.g. "data...

This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives? Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesZymergen + GinkgoCassavaTeva About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Quest 2 prices going up https://twitter.com/metaquestvr/status/1551975828442910720?s=21&t=AYmHwjCEWLEz5BmlblPGxQAcquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's... (38 kB)https://www.prnewswire.com/news-releases/ginkgo-to-acquire-zymergen-301592281.html@Cadence to acquire OpenEye, combining our molecular modeling software with their leading AI/ML, cloud solutionshttps://twitter.com/openeyesoftware/status/1551555197264187394?s=21&t=gXuRIl9uOVivwHyPXPeKNg

0:00 Bestie intros! 2:19 GDP growth is negative for a second consecutive quarter, but is the US actually in a recession? How has the White House controlled the narrative? 22:45 Looking at COVID trends with a post-COVID view: e-commerce, remote work, and how they correlate 36:33 "Inflation Reduction Act", how government subsidies can stifle innovation 59:50 Alzheimer's fraud, Ginkgo acquires Zymergen for $300M 1:17:36 Democrats backing MAGA candidates in primaries vs. more moderate republicans: savvy and cynical or too risky? Follow the besties: https://twitter.com/chamath https://linktr.ee/calacanis https://twitter.com/DavidSacks https://twitter.com/friedberg Follow the pod: https://twitter.com/theallinpod https://linktr.ee/allinpodcast Intro Music Credit: https://rb.gy/tppkzl https://twitter.com/yung_spielburg Intro Video Credit: https://twitter.com/TheZachEffect Referenced in the show: https://www.bea.gov/news/2022/gross-domestic-product-second-quarter-2022-advance-estimate#:~:text=Real%20gross%20domestic%20product%20 https://news.shopify.com/changes-to-shopifys-team https://www.google.com/finance/quote/TDOC:NYSE https://www.wsj.com/articles/whats-in-joe-manchin-and-chuck-schumers-reconciliation-deal-on-climate-health-and-tax-policy-11658973323 https://twitter.com/jamiedupree/status/1552406981637545993 https://www.nytimes.com/2022/07/24/world/africa/congo-oil-gas-auction.html https://www.science.org/content/article/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease https://www.nature.com/articles/s41380-022-01661-0 https://www.pharmaceutical-technology.com/news/ginkgo-acquire-zymergen/ https://www.nytimes.com/2022/07/26/us/politics/democrats-john-gibbs-peter-meijer.html https://twitter.com/ConanOBrien/status/1552358211986006019 https://twitter.com/maga_cy/status/1552360064693915648  

Peter Singlehurst is the Head of Private Companies at Baillie Gifford. As of 31st March 2022, funds under Baillie Gifford's management and advice totaled £277bn. The firm is owned and run by 51 of its senior executives who operate as a partnership, a structure that has endured for over a century. As for Peter, he has been with Baillie Gifford since graduating from Durham University 12 years ago and has backed some astonishing breakouts such as Wise, Grammarly and Zymergen to name a few. In Today's Episode with Peter Singlehurst We Discuss: 1.) Entry into Venture: How Peter landed his role with Baillie Gifford straight out of university? Why does Peter and Baillie Gifford prefer to hire young people without backgrounds or studies in finance? Why do they tend to be better investors? What does Peter believe are the basic building blocks that can be taught in investing? What cannot be taught and needs to be learned with experience and time? 2.) The Biggest Misnomers and Misalignments in Venture: Why does Peter believe the distinction between public vs private markets is BS? Why does Peter believe it is an advantage to invest at the same time in both public and private markets? Why does Peter think there is an inherent misalignment in venture between GPs and their LPs? 3.) Baillie Gifford: Constructing a Portfolio with £277BN: How does Baillie Gifford approach portfolio construction today? How many lines do they want to have in their portfolio? What is the right level of diversification? How does Peter think about sizing each position? How does Peter think about capital concentration across rounds vs first check being the largest? How does Peter approach outcome scenario planning? How does Peter think about downside protection and loss rates? 4.) Peter Singlehurst: The Investor: How has Peter's investing style changed over the last 10 years? What has gotten easier? What has gotten harder? What is Peter's biggest miss? How did it change his approach? What is Peter's biggest hit? What did he learn and take from this? How did the crossover funds change and impact the way that later stage venture was conducted? Item's Mentioned In Today's Episode: Peter's Fave Book: The Myth of Sisyphus Peter's Most Recent Investment: Grammarly

I speak with Dr. John Warner of Zymergen and Beyond Benign about sustainability in the chemical industry. (0:00) Introduction (1:03) Chemical industry as an actor in society and economy (4:31) Green chemistry (5:54) Teaching chemistry skills (10:50) Beyond Benign (20:11) Marketing and public relations in the chemical industry (22:24) Communication (24:03) Financing sustainability efforts (30:59) Numbers and narratives in startups

Dror is a Founding Partner at Innovation Endeavors, which he cofounded with Eric Schmidt. He invests in early-stage startups that are driving exponential rates of change in their industries, leading to a Super Evolution. Dror has invested in over 100 different companies from Seed through Series B. He led the firm's investments in Uber, SoFi, Planet, Zymergen, Freenome, Blue River Technologies, and others. Before becoming an investor, he was a team leader of R&D at NICE Systems (Nasdaq: NICE). Dror earned an MBA from Stanford Graduate School of Business and a BS in Computer Science from Ben-Gurion University. He is an ML7 Associate at Creative Destruction Lab and a member of the Steering Committee of Israel Collaboration Network.

Show Notes: 0:00 Big week for the besties: Friedberg's new raise, Sacks' new fund & more 16:30 Innovative venture strategies: internal mark ups, venture studios, deployment strategies 30:44 Zymergen's implosion: role of diligence, how to make deep tech sustainable, finding frauds 43:26 How personal risk impacts decision making on a grand scale, narratives and fundraising 59:12 Chamath & Jason share Theranos stories, Jason calling out frauds 1:07:36 Financial deplatforming, Square acquires Afterpay, Square's savvy move, fintech's future, Jack Dorsey's unique position of power 1:28:05 New Yung Spielburg banger: "Friedberg Index" Follow the besties: https://twitter.com/chamath https://linktr.ee/calacanis https://twitter.com/DavidSacks https://twitter.com/friedberg Follow the pod: https://twitter.com/theallinpod https://linktr.ee/allinpodcast Intro Music Credit: https://rb.gy/tppkzl https://twitter.com/yung_spielburg Intro Video Credit: https://twitter.com/TheZachEffect Referenced in the show: CNBC - Early Google exec got Larry Page's backing to build a start-up factory focused on saving the planet https://www.cnbc.com/2021/07/30/david-friedbergs-alphabet-backed-production-board-raised-300-million.html Medium - Announcing Craft III: $1.1 Billion for SaaS and Marketplaces https://medium.com/craft-ventures/announcing-craft-iii-1-1-billion-for-saas-and-marketplaces-c3c34448db17 CNBC - Synthetic biology company Zymergen plunges 68% after saying product revenue will be ‘immaterial' in 2022, removing CEO https://www.cnbc.com/2021/08/03/zymergen-zy-plunges-68percent-on-forecast-for-immaterial-revenue-in-2022.html Zymergen - Zymergen Provides Business Update https://www.globenewswire.com/news-release/2021/08/03/2274125/0/en/Zymergen-Provides-Business-Update.html Reuters - U.S. charges Nikola founder Trevor Milton with lying to investors https://www.reuters.com/business/autos-transportation/us-charges-nikola-founder-trevor-milton-with-lying-investors-2021-07-29 CNBC - Square to buy Australia's Afterpay in $29 billion deal as ‘buy now, pay later' trend takes off https://www.cnbc.com/2021/08/02/square-to-buy-australia-fintech-afterpay-amid-buy-now-pay-later-trend.html

Jason opens with a Founder University segment on "Startup Math" (1:48), then interviews Zymergen CEO Josh Hoffman on Biofacturing (16:45), how DNA sequencing & machine learning are enabling materials science advancements (26:35), what human capital is needed for the industry (42:53) & more.

Jason opens with a Founder University segment on "Startup Math" (1:48), then interviews Zymergen CEO Josh Hoffman on Biofacturing (16:45), how DNA sequencing & machine learning are enabling materials science advancements (26:35), what human capital is needed for the industry (42:53) & more.

What is biofacturing? How can products be made from microbes? In this episode, Dr. Zach Serber, co-founder and chief science officer of the biofacturing company, Zymergen, talks to us all about making products from microbes. He tells us all about the process of creating novel products from microbes and all of the amazing things that Zymergen does. Check out Zymergen's website: https://www.zymergen.com/ Follow Dr. Zach Serber on Twitter and LinkedIn: https://twitter.com/ZachSerber https://www.linkedin.com/in/serber/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

In der heutigen Episode möchten wir euch das Bionik Unternehmen Zymergen Unternehmen. Zymergen arbeitet mit der Natur zusammen um neue Materialien und Zusammenhänge in der Materialforschung zu finden.

The world of biotechnology is increasingly driven by data. As the number of biotech companies continues to grow, so does this industry's need for data scientists, data analysts, and other technologists. With demand for data—and the associated concerns of where to store it, how to process it, and how data pipelines will be structured—on the rise, there will be plenty of opportunities in biotech for those specializing in app development, software engineering, cloud architecture, and other fields.Kurt Thornhttps://www.linkedin.com/in/kurt-thorn-3704201/The Data Standardhttps://datastandard.io/https://www.linkedin.com/company/the-data-standard/

Meet: Marian manages the Experiments and Optimization team at Zymergen. She spent the last ten years building data science solutions for problems in remote sensing, epidemic modeling, weather science, ag-tech, and now in synthetic biology. What you'll learn: Taking advantage of innovation Relationships with science and product teams Advice if you want to get into data science If you would like to get in touch with Marian regarding anything discussed on this episode, please connect via: https://twitter.com/bayesiangirl

After earning her PhD, Crystal Humphries decided to pursue a career in data science instead. Despite her education, her early attempts to land a job fell short. There was still much for her to learn before she lands that dream job. Learn more about Crystal's trial-by-fire journey from academia to data science in this Educative Session.Watch it on YouTube HERE: https://youtu.be/XFhoQj7nzNwABOUT OUR GUESTCrystal Humphries is the first in her family to go to college and then to get a PhD. I wanted to be a professor until she saw their pay checks and levels of stress. After stumbling onto a data science-like project during my PhD, Crystal made the bold yet discouraged move into technology.Don't forget to subscribe to Educative Sessions on YouTube! ►► https://bit.ly/39sIrUNABOUT EDUCATIVEEducative (educative.io) provides interactive and adaptive courses for software developers. Whether it’s beginning to learn to code, grokking the next interview, or brushing up on frontend coding, data science, or cybersecurity, Educative is changing how developers continue their education. Stay relevant through our pre-configured learning environments that adapt to match a developer’s skill level. Educative provides the best author platform for instructors to create interactive and adaptive content in only a few clicks.More Videos from Educative Sessions: https://www.youtube.com/channel/UCT_8FqzTIr2Q1BOtvX_DPPw/ Episode 17: “Overcoming data science interviews with an academic's mindset” with Crystal Humphries of Zymergen | Educative Sessions

Nan is a managing director at Obvious Ventures, where he invests in companies solving the world’s biggest problems in sustainable systems, healthy living, and people power. At Obvious, his investments have included LabGenius, Recursion Pharmaceuticals, Darwin AI, Octave Health, Zymergen, and Planet. Prior to joining Obvious, Nan has had a mix of technology, investing, and entrepreneurship experiences including early stage tech investments at Innovation Endeavors, Product, Operations, and Finance at Gigwalk, VC and management consulting at Bain, and PM at Microsoft. Nan is also an adjunct lecturer at Stanford where he teaches a course on symbolic systems in VC and entrepreneurship.Topics:- Computational biology investments- Understanding the biology of investments- Applying digital approaches to biology- Addressing computational drug design skeptics- Managing fund cycle expectations in deep tech investing- East vs west coast investment mindsets

Are you frustrated with where you are at work? Maybe you feel like you aren't advancing as you should be, as you deserve to be, or you struggle to define your own style of leadership. Women leaders (and companies) typically focus on two areas when aiming to advance women in leadership: building business skills and combatting discrimination. However, this leaves out a crucial third and often overlooked area – internalized patriarchal programming. Our special guest today, LeeAnn Mallorie, will be addressing this, along with the importance for women to tap into their bodies and their intuition, what they can learn from them, and how it can help them advance at work. In this episode, LeeAnn Mallorie teaches us: to tap into our intuition again, which we might have stopped listening to at work to pay attention to the cues that our body is giving us a mindfulness exercise that we can use at work the importance of power poses what it means to lead like a woman For a free download, Embodied Practices for Women Leaders, go to http://bit.ly/2019LIMWLDownloads. To find out about her book, and about her women's work, please go to https://www.gutsandgrace.com. See below for more ways to learn about and stay in touch with LeeAnn Mallorie. It would really mean a lot to me if you would go to Apple Podcasts and leave me a review (hopefully a great one!), leave a 5 star rating, subscribe to this podcast so you never miss an episode, and download the episodes! And please spread the word and help our community grow! Thank you so much spending your time with me! And if you aren't following me already, you can find me on Instagram and Facebook, and click here to receive my newsletter. May you live purposefully, may you love yourself, and may you love life. Bye for now! About LeeAnn Mallorie LeeAnn Mallorie is a leadership coach and consultant who helps women tap into the wisdom of their bodies and their intuition, so that they can make a bigger impact without burning out. LeeAnn believes that the key to breaking the glass ceiling at work is a deep understanding of the intersection of leadership and resilience. She helps her clients cultivate mindful self-awareness and develop simple, reliable practices that bring their native superpowers back online at work. As the founder and CEO of Leading in Motion, LeeAnn is passionate about helping women leaders bring forward cutting-edge ideas that serve the greater good. She is committed to the win-win-win–changing industries and organizations for the better, while keeping stakeholder relations in-tact. LeeAnn has supported leaders at diverse organizations like Nasa, Mattel, Logitech, Capital One, M&T Bank, Campbells, Roche, Zymergen, Pace Women's Justice Center and the Edna McConnell Clark Foundation. Her new book, Guts and Grace, teaches women to dismantle the patriarchy, from the inside out. It will be published by Conscious Capitalism Press in January of 2020. Facebook: https://www.facebook.com/leeannmallorie Twitter: @LeeannMallorie Instagram: @lmallorie and @leeannmallorie LinkedIn: https://www.linkedin.com/in/leeannmallorie/

"[As a founder] there is no stopping. The commitment is bottomless in a way that I've never had before...and so it requires a level of emotional resilience and balance that is not the easiest thing to do," says Josh Hoffman, co-founder and CEO of biotech startup Zymergen in the latest episode of the firm's podcast, Exchanges at Goldman Sachs. Hoffman joined Jen Rubio, co-founder and chief brand officer of luggage startup Away, and Dan Dees, co-head of Goldman Sachs' Investment Banking Division to discuss what it's really like to start and scale a company. This podcast was recorded on October 18, 2018. The information contained in this recording was obtained from publicly available sources and has not been independently verified by Goldman Sachs. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the information contained in this recording and any liability as a result of this recording is expressly disclaimed. The recording should not be relied upon to evaluate any potential transaction. Goldman Sachs is not giving investment advice by means of this recording, and this recording does not establish a client relationship with Goldman Sachs. Copyright 2018 Goldman Sachs & Co. LLC. All rights reserved.

Hello and welcome back toEquity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines. This week we had the regular crew back together which was good fun. Connie took point, we had Danny mic'dup in New York, and I was onsite to help the crew natter along with BubbaMurarka, a former VC and founder who now cuts checks on his own. Thematically, this was a week of mega rounds so we had little choice but to go over more than a few.

This week we had the regular crew back together which was good fun. Connie took point, we had Danny mic'd up in New York, and I was onsite to help the crew natter along with Bubba Murarka, a former VC and founder who now cuts checks on his own. Thematically, this was a week of mega rounds so we had little choice but to go over more than a few. And Uber is out there doing its IPO thing. So, we started with cars and pivoted into rounds.

This week we had the regular crew back together which was good fun. Connie took point, we had Danny mic'd up in New York, and I was onsite to help the crew natter along with Bubba Murarka, a former VC and founder who now cuts checks on his own. Thematically, this was a week of mega rounds so we had little choice but to go over more than a few. And Uber is out there doing its IPO thing. So, we started with cars and pivoted into rounds.

Joshua Hoffman, co-founder and CEO of industrial-chemicals maker Zymergen, details how his intellectual dabbling in college and the courage to work on his weaknesses prepared him to be a broadminded business leader. He urges aspiring entrepreneurs to become good storytellers and build strong teams of divergent thinkers, even if they drive you nuts. Hoffman explains why it's all worth the pain.

Joshua Hoffman, co-founder and CEO of industrial-chemicals maker Zymergen, details how his intellectual dabbling in college and the courage to work on his weaknesses prepared him to be a broadminded business leader. He urges aspiring entrepreneurs to become good storytellers and build strong teams of divergent thinkers, even if they drive you nuts. Hoffman explains why it's all worth the pain.

Joshua Hoffman, co-founder and CEO of industrial-chemicals maker Zymergen, details how his intellectual dabbling in college and the courage to work on his weaknesses prepared him to be a broadminded business leader. He urges aspiring entrepreneurs to become good storytellers and build strong teams of divergent thinkers, even if they drive you nuts. Hoffman explains why it's all worth the pain.

The show you’re listening to features my interview with Erin Shellman. Erin is a statistician and data science manager with Zymergen, a company using robots and machine learning to engineer better microbes. If you’re wondering what exactly that means, I was too, and we talk about it in the interview. Our conversation focuses on Zymergen’s use of Apache Airflow, an open-source data management platform originating at Airbnb, that Erin and her team uses to create reliable, repeatable data pipelines for its machine learning applications. A quick note before we dive in: As is the case with my other field recordings, there’s a bit of unavoidable background noise in this interview. Sorry about that! The show notes for this episode can be found at https://twimlai.com/talk/41